Welcome to our dedicated page for Immunovant SEC filings (Ticker: IMVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunovant, Inc. (Nasdaq: IMVT) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view into its operations as a clinical-stage immunology company. These documents complement Immunovant’s focus on developing FcRn-targeting monoclonal antibodies, including IMVT-1402 and batoclimab, for IgG-mediated autoimmune diseases.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q, where Immunovant discusses research and development activities, general and administrative expenses, net losses and cash balances. These filings also describe the company’s single operating segment, risk factors related to clinical development and financing needs, and its relationship with controlling stockholder Roivant Sciences Ltd.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have addressed quarterly financial results, leadership changes, executive employment agreements, separation arrangements with senior officers, clinical program updates in Graves’ disease and other indications, and outcomes of the company’s annual meeting of stockholders. These filings can include or reference press releases with detailed clinical and financial information.
Immunovant’s proxy statements on Schedule 14A offer insight into corporate governance, board composition, executive compensation and stockholder voting matters. The definitive proxy statement also outlines the company’s corporate history, including its business combination that resulted in the current Immunovant, Inc. structure.
Through Stock Titan, users can access these SEC filings as they are made available on EDGAR, along with AI-powered summaries that help explain key points in lengthy documents. This includes highlighting major changes in clinical strategy, financing transactions, governance decisions and other disclosures that shape the risk and opportunity profile for IMVT.
Immunovant, Inc.’s Chief Legal Officer Christopher Van Tuyl reported a mandated tax-related share sale. On March 18, he disposed of 2,877 shares of common stock at $24.97 per share to cover tax withholding obligations from recently vested restricted stock units. After this transaction, he directly holds 147,053 shares. The company notes this "sell to cover" sale was required under its tax withholding policy and was not a discretionary trade.
Immunovant, Inc. Chief Operating Officer Gloria Melanie reported three open-market sales of common stock that together totaled 3,238 shares on February 25, 2026. The reported transactions were executed at weighted average prices of $26.98, $28.16, and $28.90 per share.
According to the footnotes, these shares were sold to cover tax withholding obligations arising from the vesting and settlement of 6,872 restricted stock units that vested on February 18, 2026. The filing states that the sales were mandated under a “sell to cover” arrangement and do not represent discretionary trading decisions by the officer.
A holder of IMVT common stock has filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 5,800 common shares through Morgan Stanley Smith Barney LLC, with an approximate sale date of February 10, 2026 on the NASDAQ.
The shares to be sold were acquired as restricted stock from the issuer in January 2026 in two grants of 3,770 and 2,030 shares, both fully paid on their acquisition dates. The filing also lists recent sales of common shares by Michael Geffner over the prior three months, including multiple transactions in November 2025 and January 2026.
Immunovant, Inc. reported another quarter of heavy investment in its autoimmune pipeline, led by FcRn inhibitor IMVT-1402, with no product revenue yet. For the three months ended December 31, 2025, net loss was $110.6 million, similar to the prior year.
Quarterly research and development expenses were $98.9 million, reflecting multiple potentially registrational trials across Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, CIDP and Sjögren’s disease, plus a proof‑of‑concept study in cutaneous lupus. General and administrative expenses fell to $15.4 million as corporate spending moderated.
The company strengthened its balance sheet with a December 2025 underwritten equity offering of 26.2 million shares at $21.00, generating net proceeds of $543.6 million. Cash and cash equivalents rose to $994.5 million as of December 31, 2025, which management believes can fund announced indications through a potential commercial launch of IMVT-1402 in Graves’ disease.
Immunovant, Inc. reported a fiscal third-quarter 2025 net loss of $110.6 million, or $0.61 per share, driven mainly by research and development spending as it advances its autoimmune pipeline.
For the quarter ended December 31, 2025, R&D expenses were $98.9 million and general and administrative expenses were $15.4 million, with non-GAAP R&D and G&A at $91.1 million and $10.6 million, respectively. Nine-month net loss totaled $357.8 million, or $2.04 per share, with non-GAAP net loss of $312.9 million.
Cash and cash equivalents reached $994.5 million as of December 31, 2025, supported by an underwritten financing that generated approximately $550 million in gross proceeds, which the company believes extends its cash runway to the potential launch of IMVT-1402 in Graves’ disease. Key programs include a fully enrolled potentially registrational trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis, with topline data expected in the second half of 2026, additional potentially registrational IMVT-1402 trials across several autoimmune indications, and Phase 3 batoclimab data in thyroid eye disease expected in the first half of 2026.
Immunovant Chief Technology Officer Jay S. Stout reported selling 1,977 shares of common stock at $26.03 per share. After this sale, he beneficially owns 197,634 shares directly.
The filing explains that this sale was not a discretionary trade. It was a mandated “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units. Of an earlier grant of 100,000 RSUs made on April 17, 2023, 6,250 RSUs vested on January 17, 2026, triggering the tax-related sale.
Immunovant, Inc. reported insider share sales by its Chief Technology Officer, Jay Stout, tied to RSU tax withholding. On January 7, 2026, he sold 1,148 shares of common stock at a weighted average price of $26.51 per share and 55 shares at a weighted average price of $26.92 per share. These sales were executed to cover tax withholding obligations from the vesting and settlement of restricted stock units and were mandated by the company’s “sell to cover” election, rather than being discretionary trades. Following the reported transactions, he directly held 199,611 shares of Immunovant common stock.
Immunovant, Inc. is offering 26,200,000 shares of common stock at $21.00 per share, for gross proceeds of $550.2 million. Roivant Sciences, its controlling shareholder, has agreed to buy 16,666,666 of these shares at the same price, and the underwriter will not receive fees on Roivant’s portion.
The company expects to receive approximately $543.7 million in net proceeds, which it plans to use, together with existing cash, primarily to advance clinical trials of its lead anti-FcRn antibody IMVT-1402, with any remainder for working capital and other general corporate purposes. Management currently expects this capital, plus cash on hand, to fund operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 for Graves’ disease.
Immunovant is a clinical-stage immunology company developing IMVT-1402 and batoclimab for multiple autoimmune, autoantibody-driven diseases, including difficult-to-treat rheumatoid arthritis, Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease. The offering will increase net tangible book value per share from $2.98 to an estimated $5.30, but investors paying $21.00 per share will face immediate dilution of $15.70 per share.
Immunovant, Inc. (IMVT) reported an insider transaction by its Chief Operating Officer, Melanie Gloria. On November 20, 2025, she sold 10,251 shares of common stock at a weighted average price of $23.54 per share and an additional 2,375 shares at a weighted average price of $23.97 per share.
These sales were made to cover tax withholding obligations related to the vesting and settlement of previously granted restricted stock units, following the company’s required “sell to cover” procedure. After these transactions, she beneficially owned 173,511 shares of Immunovant common stock directly.
Immunovant, Inc. reported that Michael Geffner, M.D., M.B.A., ceased serving as its Chief Medical Officer effective November 21, 2025, as part of a restructuring of the company’s R&D leadership under Chief Executive Officer Eric Venker, M.D., PharmD. The company and Dr. Geffner entered into a Separation Agreement and General Release that provides severance benefits consistent with his existing employment agreement and includes a standard release of claims in favor of the company.
To support continuity, Dr. Geffner will provide consulting services through April 30, 2026. During this consulting period, his outstanding equity awards will continue to vest under their current terms, and any unvested awards scheduled to vest during the consulting period will fully vest if a change in control occurs in that timeframe. Vested stock options may be exercised until the earlier of nine months after his consulting ends or their original expiration dates.